Form 4: Immix Biopharma CEO Ilya Rachman Acquires 340,000 Stock Options

Immix Biopharma's CEO and Chairman, Ilya Rachman, acquired 340,000 stock options at an exercise price of $2.04 on June 11, 2024, according to a Form 4 filing.

Summary

• Ilya Rachman, CEO and Chairman of Immix Biopharma, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on June 11, 2024.
• Rachman acquired 340,000 stock options with an exercise price of $2.04.
• These options vest in 48 equal monthly installments, contingent upon continued service with the company.
• The options expire on June 11, 2034.
• Rachman directly owns 1,136,259 shares of Immix Biopharma common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The CEO acquiring stock options generally signals confidence, but it's a routine part of compensation.

Positives

• The CEO's acquisition of stock options could be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

This type of stock option grant is a common practice in the biopharmaceutical industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen routinely grant stock options to their executives as part of their overall compensation strategy.
• The vesting schedule of 48 months is also typical for these types of grants.

Stakeholder Impact

• The stock option grant could potentially incentivize the CEO to improve company performance, benefiting shareholders.

Key Dates